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Numerous clinical and environmental condi-
tions result in elevated thrombin generation
with subsequent thrombus formation not
only in adults but also in children (Andrew
et al. 1994; Schmidt and Andrew 1995).
Both genetic and environmental factors have
been established as causes of cardiovascular
disease (CVD)—for example, coronary heart
disease, stroke, and deep venous thrombosis
(DVT) (Edwards et al. 1999; Stephens and
Humphries 2003). Stroke in children is a rare
disease with an estimated incidence of 2.6 per
100,000 per year (Schoenberg et al. 1978),
with half of the events reported presenting as
acute ischemic strokes (AISs). Risk factors of
AIS in children include congenital heart mal-
formations, vascular abnormalities, endothe-
lial damage, infectious diseases, and collagen
tissue diseases, as well as some rare inborn
metabolic disorders (Kirkham et al. 2000;
Nicolaides and Appelton 1996). In addition,
it has recently been demonstrated that hyper-
coagulable states associated with a) the pres-
ence of the factor (F) V G1691A mutation,
the FII G20210A variant, b) increased con-
centrations of lipoprotein(a) [Lp(a)], and
c) deficiency states of antithrombin, protein
C, protein S, and tissue factor pathway
inhibitor (TFPI) represent risk factors for AIS
in childhood (Düring et al. 2004; Haywood
et al. 2005; Israels and Seshia 1987; Nowak-
Göttl et al. 1999a, 1999b; Sträter et al.
2002). In addition, measurable risk factors
for CVD in adults further include traits such
as obesity, high blood pressure, elevated
serum cholesterol, and low levels of high-den-
sity lipoprotein (HDL), with an aggregation
within families (Gardner et al. 1996;
Lamarche et al. 1998; Stampfer et al. 1996).
These studies suggest that genetic factors are
important in determining CVD. In adult
cohorts, however, there is increasing evidence
that in addition to genetic risk factors inﬂu-
encing lipid and coagulation factor levels,
modifiable environmental factors such as
smoking, alcohol consumption, diet, or exer-
cise are likely to contribute to the pathogene-
sis of CVD (Czerwinski et al. 2004;
Middelberg et al. 2002; Mosher et al. 2005;
Perusse et al. 1997). Developing statistical
methodology allows investigation of traits
whose susceptibility to familial influences
impinges on the risk of diseases at interest
(Almasy and Blangero 1998). The identiﬁca-
tion of heritable and environmental factors
possibly influencing a condition at risk
should be a prerequisite for the search
for a) quantitative trait loci affecting such
traits and b) household effects modulating the
risk of disease. Thus far, such epidemiologic
approaches in various population cohorts of
different size—for example, healthy twins
(Ariens et al. 2002; de Lange et al. 2001;
Heller et al. 1993; Middelberg et al. 2006;
Snieder et al. 1997), Spanish idiopathic
thrombosis families (Souto et al. 2000), rela-
tives of protein C–deﬁcient pedigrees (Vossen
et al. 2004), or parent–offspring pairs from
national health surveys (Freeman et al. 2002;
Saunders and Gulliford 2006)—have been
performed mainly in adult cohorts. Although
these studies included pediatric offspring,
they did not focus primarily on pediatric dis-
ease. To date, such studies in families with
first onset of stroke during early childhood
are lacking. Because estimates for heritability
may provide insights into the relative impor-
tance of genetic and environmental variables
associated with AIS in children, the present
study was conducted. 
Methods
Ethics. The present study was performed in
accordance with the ethical standards laid
down in the updated version of the 1964
Declaration of Helsinki (World Medical
Association 2002) and was approved by the
medical ethics committee of the University of
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BACKGROUND: The identification of heritable and environmental factors possibly influencing a
condition at risk should be a prerequisite for the search for the proportion of variance attributable
for shared environmental effects (c2) modulating the risk of disease. Such epidemiologic approaches
in families with a ﬁrst acute ischemic stroke during early childhood are lacking. 
OBJECTIVES: Our goal was to estimate the phenotypic variation within lipid concentrations and
coagulation factor levels and to estimate the proportions attributable to heritability (h2r) and c2 in
pediatric stroke families. 
METHODS: Blood samples were collected from 1,002 individuals from 282 white stroke pedigrees.
We estimated h2r and c2 for lipoprotein (a) [Lp(a)], cholesterol, high-density lipoprotein, low-
density lipoprotein (LDL), fibrinogen, factor (F) II, FV, FVIIIC, von Willebrand factor (vWF),
antithrombin, protein C, protein S, plasminogen, protein Z, total tissue factor pathway inhibitor
(TFPI), prothrombin fragment F1.2, and D-dimer, using the variance component method in
sequential oligogenetic linkage analysis routines.
RESULTS: When incorporating h2r and c2 in one model adjusted for age, blood group, sex, smoking,
and hormonal contraceptives, signiﬁcant h2r estimates were found for Lp(a), LDL, ﬁbrinogen, pro-
tein C, and protein Z. In addition to the signiﬁcant h2r estimates, c2 showed a signiﬁcant effect on
phenotypic variation for ﬁbrinogen, protein C, and protein Z. A signiﬁcant c2 effect was found for
cholesterol, and plasma levels of FII, FV, vWF, antithrombin, protein S, plasminogen, and TFPI,
ranging from 9.3% to 33.2%. 
CONCLUSIONS: Our research stresses the importance of research on the genetic variability and
lifestyle modiﬁcations of risk factors associated with pediatric stroke. 
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2008]Münster, Germany. With written parental
consent, term neonates and children with
confirmed diagnosis of AIS who were ≤ 18
years of age at onset, biological brothers and
sisters, and available parents (nuclear family)
were enrolled.
Study population and study design. From
July 1996 to August 2006, 1,002 household
members of 282 white pediatric index patients
enrolled in the Münster stroke database were
analyzed (Düring et al. 2004; Nowak-Göttl
et al. 1999b; Sträter et al. 2002). AIS was con-
ﬁrmed by standard imaging methods—duplex
sonography, magnetic resonance imaging, and
computerized tomography, and/or magnetic
resonance angiography (Nowak-Göttl et al.
1999b; Sträter et al. 2002). All family mem-
bers enrolled were personally interviewed
regarding their medical history, surgery,
trauma, immobilization, infections, pregnan-
cies, and use of any medication such as oral
contraceptives, hormone replacement therapy,
antibiotics, lipid-lowering therapy, and
antihypertensive or antidiabetic drugs. In
addition, data on objectively confirmed
thromboembolic events including age at onset,
triggering factors, imaging methods per-
formed, and use of antithrombotic/antiplatelet
therapy and its duration were documented.
Preterm AIS infants and patients > 18 years of
age at ﬁrst AIS onset were not included in the
present study. In addition, patients with sus-
pected AIS without the diagnosis being con-
firmed by an independent experienced
pediatric neuroradiologist were excluded from
the present survey. Seven adult patients using
vitamin K antagonists were excluded from the
analysis for vitamin K–dependent coagulation
proteins, D-dimer, and prothrombin F1.2. In
addition, we excluded 18 parents from the
analysis for lipid measurements who were
taking lipid-lowering medication. 
Blood sample collection. We collected
blood samples from patients and relatives in
the morning after a 12-hr fasting period (for
infants, 4–6 hr); samples were drawn by
peripheral venipuncture into plastic tubes con-
taining 1/10 by volume of 3.8% trisodium cit-
rate (Sarstedt, Nümbrecht, Germany) and
were immediately placed on melting ice.
Serum plastic tubes purchased from Sarstedt
were used to collect samples to measure lipid
components. The blood samples from patients
were collected 6–12 months after the acute
thrombotic event and at least 6 weeks apart
from anticoagulation. Platelet-poor plasma or
serum was prepared by centrifugation at
3,000 × g and 4°C for 2 × 20 min, aliquoted
in polystyrene tubes, stored at –70°C, and
thawed immediately before assay. DNA extrac-
tion was performed by a spin column proce-
dure (QIAGEN GmbH, Hilden, Germany) as
previously described (Junker et al. 1999). For
the present study, blood samples were drawn
from otherwise healthy patients, relatives, and
controls with normal hemograms and no
evidence of further diseases.
Laboratory analyses. With written
parental consent, laboratory analyses includ-
ing Lp(a), kringle 4 repeats, total cholesterol,
low-density lipoprotein (LDL), HDL, the FV
G1691A mutation, the FII G20210A variant,
fibrinogen, FV, chromogenic FII, FVIIIC,
von Willebrand factor (vWF) antigen,
antithrombin, protein C, free protein S, pro-
tein Z, plasminogen, total TFPI, D-dimer,
prothrombin fragment f1.2 (f1.2), and
antiphospholipid antibodies/lupus anti-
coagulants were performed as previously
described (Heller et al. 2003; Junker et al.
1999; Kreuz et al. 2006; Nowak-Göttl et al.
1999a, 1999b; Ravi et al. 1998). Based on the
availability of appropriately stored serum and
plasma samples, the number of individuals
per assay varied from 582 to 1,002. 
Statistics. Statistical analyses were per-
formed using the StatView 5 (SAS Institute
Inc., Cary, NC, USA) and SOLAR software
packages (Almasy and Blangero 1998).
Because nonparametric tests are less depen-
dent on the shape of the underlying distribu-
tions, continuous data are presented as
medians (minimum–maximum) and are eval-
uated statistically by using the Wilcoxon–
Mann–Whitney U test or Kruskal–Wallis
test, corrected for multiple testing according
to Bonferroni. On the assumption that multi-
ple genes with small effects inﬂuence pediatric
AIS, as well as the premise of having normally
distributed traits, we estimated heritability
(h2r) for lipid concentrations and coagulation
factor levels using the variance component
method implemented in SOLAR. This
method allows the total phenotypic variance
to be partitioned into a proportion caused by
polygenic effects and a proportion caused by
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Table 1. Pedigree characteristics (index children, biological siblings, and parents).
AIS children  Siblings Parents
Characteristic (n = 282) (n = 216) (n = 504)
Disease/health status
AIS/DVT/MI (no.) 282/—/— 3/—/— 1/8/3
Age (years) at blood collection [median (min–max)] 4 (0.1–18) 6 (0.1–18) 35 (17–65)*
Male sex [no. (%)] 152 (54) 115 (53) 241 (47.9)
BMI (kg/m2) [median (min–max)] 16.0 (7.9–30.9) 17.4 (10.8 –29.3) 24.6 (17.7–46.9)*
Risk factors
FVG1691A [no. (%)] 41 (14.5) 23 (10.6) 59 (11.7)
Prothrombin G20210A [no. (%)] 19 (6.7) 6 (2.8) 18 (3.6)
Antithrombin-/protein C–/protein S–deﬁciency/APS (no.) 0/4/0/4 0/0/0/0 0/4/0/1
Lp(a) > 30 mg/dL [no. (%)] 72 (25.5) 53 (24.4) 131 (26.0)
Smoking > 12 years of age [no. (%)] 3 (1.1) 10 (4.6) 77 (15.3)*
Use of oral contraceptives [no. (%)] — 6 (2.8) 31 (11.8)
Therapy 
Aspirin/vitamin K antagonists (no.) 25/— —/— 3/7
Antihypertensive/antidiabetic/lipid-lowering therapy (no.) 4/0/0 0/0/0 75/5/18
Abbreviations: —, no event; max, maximum; MI, myocardial infarction; min, minimum. 
*Compared with children, p < 0.05. 
Table 2. Median (min–max) values of lipid and coagulation factor levels in index patients and relatives.
Individuals AIS children Siblings Parents
Characteristic tested (no.) (n = 282)  (n = 216) (n = 504)
Lipid components [median (min–max)]
Lp(a) (mg/dL) 1,002 14 (0–168) 16 (0.6–126) 18 (1–201)
Lp(a) kringle 4 repeats 971 27 (12–37) 25 (13–37) 27 (8–37)
Total cholesterol (mg/dL) 870 161 (91–249) 160 (96–222) 192 (93–323)*
LDL (mg/dL) 868 85 (24–177) 87 (38–171) 111 (22–236)*
HDL (mg/dL) 870 55 (25–104) 58 (29–96) 59 (27–111)
Coagulation factors [median (min–max)]
Fibrinogen (mg/dL) 1,002 247 (128–572) 248 (36–528) 260 (136–572)
FII (%) 1,002 98 (24 –172) 98 (18–164) 107 (62–201)*
FV (%) 1,002 100 (25–195) 105 (13–1074) 111 (50–182)
FVIIIC (%) 934 102 (39–192)* 105 (59–184) 118 (34–236)
vWF (% ) 870 103 (19–279) 102 (25–220) 109 (38–281)
Antithrombin (%) 820 103 (71–131) 107 (66–136) 103 (74–150)
Protein C (%) 960 89 (23–196) 91 (18–174) 109 (39–200)*
Protein S (%) 960 94 (42–162) 90 (38–156) 94 (35–188)
Protein Z (µg/mL) 582 1.3 (0.21–8) 1.4 (0.44–3.2) 1.6 (0.33–4.9)*
Plasminogen (%) 934 94 (44–135) 96 (49–151) 105 (62–207)*
TFPI (ng/mL) 865 57 (21–116) 40 (28–113) 47 (19–116) 
D-dimer (mg/L) 752 0.16 (0–0.6) 0.18 (0–2.0) 0.12 (0–1.6)
Prothrombin F1.2 (nmol/L) 826 0.8 (0–6.5) 0.7 (0.1–4.5) 0.8 (0–8.1)
Abbreviations: max, maximum; min, minimum. 
*Compared with children, p < 0.05. random environmental effects, including the
proportion of variance in a trait that can be
attributed to common environmental factors/
household effects (c2). The calculated h2r thus
estimates the total variance of a trait explained
by additive genetic effects. Before variance
component analysis, we tested the phenotypic
distribution using the Kolmogorov–Smirnov
test to assure normal distribution of the trait
within the population, as required for
parametric analytic procedures. Traits failing
the requirements of normality in the
Kolmogorov–Smirnov test were transformed
through a logarithmic transformation and
retested for normalcy. All traits were normally
distributed except for Lp(a), which was sub-
sequently logarithmically transformed and
then passed the Kolmogorov–Smirnov test for
normalcy. To adjust for covariates possibly
explaining the phenotypic h2r or c2 variation
in this pediatric AIS family study, we entered
the FV G1691A mutation, the prothrombin
G20210A variant, age at blood sample collec-
tion, blood group, sex, smoking, and the use
of oral contraceptives, into the ﬁnal model of
the variance component analysis. Both
variance components and covariates were esti-
mated simultaneously by maximum likeli-
hood techniques as implemented in SOLAR.
We tested the null hypothesis of no genetic
effect (h2r = 0) on phenotype with a likeli-
hood ratio test by comparing the likelihood of
a restricted model in which parameter h2r was
constrained to a value of 0 with that for a
general model in which the same parameter
was estimated. Standard errors were calcu-
lated as part of the iterations preceding the
variance component analysis. Because our
samples were ascertained via index patients, we
conditioned the likelihood of a family on a
phenotype of the initial proband to account in
part for the nonrandom sampling (Comuzzie
and Williams 1999) as implemented in
SOLAR. We calculated prevalence rates of
prothrombotic risk factors in patients and
family members by descriptive statistics and
compared them by chi-square analysis or by
Fisher’s exact test, if appropriate. The criterion
for statistical signiﬁcance was set at α = 0.05.
p-Values were based on two-sided test. 
Results
Study population. One thousand two subjects
were recruited and examined from 282 pedi-
grees and households including 498 children;
the structure of pedigrees varied from 3 to 10
individuals, with a median of three family
members sharing one household. The main
characteristics of the 1,002 family members
are shown in Table 1. The median age of the
index patients was 4 years, and the whole pop-
ulation, of which 50.6% members were male,
had a median age of 22 years. Whereas sex,
body mass index (BMI), and the proportion of
prothrombotic risk factors did not differ sig-
nificantly between the offspring groups, age
at blood sample collection and the rate of
smoking was signiﬁcantly increased in parents.
Table 2 describes median (minimum–
maximum) values of the lipid concentrations
and coagulation factors investigated. Again,
there was no statistical difference between the
pediatric groups tested. In contrast, as expected,
median (minimum–maximum) values of
cholesterol, LDL, FII, protein C, protein Z,
and plasminogen were signiﬁcantly higher in
parents compared with their offspring. 
Heritability analysis. When we measured
h2r without accounting for possible environ-
mental effects, h2r estimates were highly
signiﬁcant for lipid concentrations and coagu-
lation factor levels investigated except for
F1.2. The significant proportion of pheno-
typic variance explained by h2r ranged from
11.8% for cholesterol to 78.8% for Lp(a)
kringle 4 repeats [Supplemental Material,
Table 1 (online at http://www.ehponline.org/
members/2008/10754/suppl.pdf)]. 
Heritability analysis including c2 esti-
mate. When incorporating h2r and c2 in one
model adjusted for modiﬁers, such as the FV
G1691A mutation, the FII G20210A variant,
age at blood sample collection, blood group,
sex, smoking, and the use of oral contracep-
tives in females, we found high and signifi-
cant h2r estimates for Lp(a) serum levels,
Lp(a) kringle 4 repeats, LDL, ﬁbrinogen, pro-
tein C, and protein Z, with a corresponding
phenotypic variance explained by genes of
84.3, 76.5, 24.3, 22.5, 17.7, and 42.3%
respectively. In addition to the signiﬁcant h2r
estimates, c2 showed significant effects on
phenotypic variation for ﬁbrinogen (11.7%),
protein C (20.1%), and protein Z (30.2%). A
signiﬁcant c2 effect without evidence for heri-
tability was found for cholesterol (16.3%) and
plasma levels of FII (20.8%), FV (9.3%),
antithrombin (30.0%), protein S (33.2%),
plasminogen (20.3%), TFPI (24.8%), and
vWF (15.8%). Of note, the proportion of
phenotypic variance explained by smoking
alone was 4% for cholesterol, LDL, and pro-
tein S. For most of the traits under study, the
model with the best fit was the household
polygenic model, except for Lp(a) (polygenic
model), antithrombin, D-dimer, FII, and FV
(household model). The sporadic model was
the best fit model to analyze prothrombin
fragment 1.2. In Table 3, we summarize h2r,
c2 estimates, and the role of modifiers if
applicable for all lipid concentrations and
coagulation factors measured.
Discussion
The present study was performed to identify
heritability and environmental factors possibly
influencing AIS in white children and their
families. This is the ﬁrst large-scale family study
of the genetics of quantitative variation in puta-
tive risk factors associated with AIS in a cohort
of children and their young parents. The high-
est estimates were found for measures of Lp(a)
and protein Z, and lower but still signiﬁcant
heritabilities were seen for LDL, fibrinogen,
and protein C. Our ﬁndings are in accordance
with previous data obtained predominantly in
adults investigated for h2r and c2 incorporated
in one model (Middelberg et al. 2002; Snieder
et al. 1997; Vossen et al. 2004). In addition to
the h2r estimates mentioned previously, in the
present survey a significant concomitant c2
effect was found for protein Z, protein C, and
ﬁbrinogen. We conﬁrmed a shared c2 effect for
levels of vWF, which has previously been
shown by Vossen et al. (2004) in a large pedi-
gree of a protein C–deﬁcient family.
Elevated Lp(a) plays a role for ﬁrst AIS in
white children and also represents a risk factor
for early stroke recurrence in this cohort
(Nowak-Göttl et al. 1999b; Sträter et al.
Heritability and household estimates in children with stroke
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Table 3. Proportion of phenotypic variance explained by covariates (%), h2r, and c2 (% ± SE).
Factor of interest  Covariates (%) h2r ± SE  p-Value c2 ±S E p-Valuea
Lp(a) R 84.3 ± 9.5 < 0.0001 0.4 ± 6.5 0.5
Lp(a) kringle 4 repeats R 76.5 ± 8.5 < 0.0001 8.0 ± 6.7 0.11
Cholesterol (total) A/S (23.5) 9.3 ± 1.3 0.23 16.3 ± 6.5 0.006
HDL A/G/S (10.0) 15.7 ± 14.6 0.14 9.4 ± 7.2 0.1
LDL A/G/S (16.8) 24.3 ± 13.1 0.034 10.2 ± 6.6 0.060
Fibrinogen A/G (2.5) 22.5 ± 12.7 0.038 11.7 ± 6.4 0.035
FII A/G/FII (11.8) 0 0.5 20.8 ± 3.5 0.0001
FV A (0.4) 0 0.5 9.3 ± 2.3 0.002
FVIIIC A/G (3.5) 5.9 ± 1.8 0.37 12.1 ± 8.3 0.07
vWF FII (0.001) 23.4 ± 16.1 0.075 15.8 ± 8.1 0.024
Antithrombin A (2.6.) 0 0.5 30.0 ± 3.8 < 0.0001
Protein C A (12.2) 17.7 ± 10.7 0.049 20.1 ± 5.6 0.0002
Protein S A/G/S (15.2) 14.9 ± 11.6 0.099 33.2 ± 6.3 < 0.0001
Protein Z A/G/H (1.6) 42.3 ± 11.0 0.0001 30.2 ± 8.5 0.0002
Plasminogen A/G/S/FII (6.6) 18.2 ± 11.9 0.07 20.3 ± 6.4 0.0008
TFPI A/G 0 0.5 24.8 ± 5.5 0.009
D-dimer FV/G/S (5.3) 0 0.5 7.5 ± 3.6 0.13
Prothrombin fragment F1.2 R 0 0.5 R —
R, removed from the model. 
aAdjusted for age (A), FII G20210A (FII), FV G1691A (FV), sex (G), use of oral contraceptives (H), and smoking (S). 2002). Based on the literature, heritability
estimates of Lp(a) are age independent
(Middelberg et al. 2006; Snieder et al. 1997).
Our finding is in line with the observation
that Lp(a) in Europeans is determined in most
cases by a single gene located on chromosome
6q26-27 (Scholz et al. 1999), identiﬁed as the
major quantitative trait locus, and that at least
a second locus, recently reported (Broeckel
et al. 2002), might be involved. Vossen et al.
(2004) reported on high heritability estimates
for protein Z (66.7%), with an environmental
effect of 6.6%. In our study, however, based
mainly on the different study design, h2r for
protein Z was lower—for example, 42.3%,
with a shared c2 estimate of 30.2%. Although
the information on protein Z heritability esti-
mates was congruent, contradictory data have
been reported for protein Z plasma levels asso-
ciated with stroke in adults. On one hand, AIS
was associated with low protein Z concentra-
tions (Vasse et al. 2001); on the other hand,
elevated protein Z concentrations were associ-
ated with AIS in adults (Kobelt et al. 2001;
Lichy et al. 2004; Staton et al. 2005). Because
the protein Z phenotypes are inﬂuenced not
only by genes but also by acute-phase reac-
tions (McQuillan et al. 2003), the identiﬁca-
tion of additive genetic effects inﬂuencing the
variability of this phenotype will contribute to
the future understanding of the role of protein
Z in adult or pediatric AIS. 
The main difference of our study from
previous reports is based on the additional
estimation of c2 effects: Here we present an
important inﬂuence of the shared c2 estimates
on phenotypic variation explained by genes
adjusted for FV G1691A, FII G20210A, age
at blood sample collection, blood groups, sex,
smoking, use of hormonal contraceptives for
cholesterol, and plasma levels of FII, FV,
antithrombin, protein S, plasminogen, and
TFPI, with signiﬁcant estimates ranging from
9.3% for FV to 33.2% for protein S. One
reason for the contradictory results relating to
plasma levels of FII and FV, respectively,
might be the fact that in our analysis FV
G1691A and FII G20210A variants were
introduced as covariates in the analysis. 
In our family study we included 498 chil-
dren ≤ 18 years of age with a median age of
5 years, which means that the duration of the
parent–offspring pair relationships was at least
5 years. Because our population differs in age
and the source of CVD—pediatric AIS—from
the studies previously published (Ariens et al.
2002; Beekman et al. 2002; de Lange et al.
2001; Heller et al. 1993; Middelberg et al.
2002, 2006; Perusse et al. 1997; Saunders and
Gulliford 2006; Snieder et al. 1997; Souto
et al. 2000; Vossen et al. 2004), our data
strengthen the hypothesis that except for Lp(a)
concentrations, age at investigation as well as
different underlying CVDs play a role with
respect to the proportion of phenotypic vari-
ance explained by additive genetic effects
(Heller et al. 1993; Snieder et al. 1997). The
young AIS cohort presented here and collected
in the Münster pediatric stroke database,
including index children, brothers, and sisters
as well as parents (nuclear families), offers the
unique opportunity for longitudinal subject
follow-up, scheduled at a 5-year interval to
obtain additional information on genetic and
environmental variations in this AIS cohort. 
In addition to the attributed magnitude
of the c2 effect and the age at recruitment, the
study design chosen also influences results
obtained from family-based surveys. The
study populations reported so far differed not
only by geographic enrollment but also by
sample size and subject selection. Twin stud-
ies were performed for lipid measurements by
Heller et al. (1993), Snieder et al. (1997), and
Middelberg et al. (2002, 2006), and heritabil-
ity estimates for coagulation factors in healthy
twins were measured by de Lange et al.
(2001) and Ariens et al. (2002) in the United
Kingdom. Souto et al. (2000) estimated heri-
tability in family members of probands with
idiopathic thrombophilia in Spain, and
Vossen et al. (2004) enrolled relatives from a
large protein C–deficient family. Subject
recruitment from healthy families in the
United Kingdom was performed by Freeman
et al. (2002), and a small, two-generation
pedigree study from the U.K. national health
survey was recently published by Saunders
and Gulliford (2006). Table 4 summarizes
studies measuring h2r as well as c2 (Ariens
et al. 2002; de Lange et al. 2001; Mitchell
et al. 1996; Saunders and Gulliford 2006;
Souto et al. 2000; Vossen et al. 2004). Thus,
we suggest that the lower heritability reported
in the present two-generation pedigrees of
young stroke children, their parents, and sib-
lings, with a median of three nuclear subjects
per household compared with other studies,
Nowak-Göttl et al.
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Table 4. Comparison of h2r and c2 estimates.
United Kingdom United Kingdom
SAFHS Gait (Ariens et al. 2002; Vermont (Saunders and Münster
Our study (Mitchell et al. 1996) (Souto et al. 2000) De Lange et al. 2001) (Vossen et al. 2004) Gullifort 2006) (Nowak-Göttl et al. 2008)
Households/pedigrees/ 655/42/1,236 153/21/397 491 twin pairs 181/1/322 6,183/—/17,690 282/282/1,002
individuals (no.)
Age [years (min–max)]  16–94 37.7 (< 1–88) 18–79/21–73 31.3 (1–90) Adults > 16 years 22 (0.1–65)
CVD Healthy community- Idiopathic DVT Community-based  Protein C–deﬁcient Healthy community- Pediatric stroke
based cohort > 45 years twins family based cohort cohort
Ethnicity Mexican American White Spanish  White White French Canadian White (1,308 nonwhite) White German
Cohort h2rc 2 h2rc 2 h2rc 2 h2rc 2 h2rc 2 h2rc 2
Lp(a) 69* 5 — — — — — — — — 84.3* 0.4
Cholesterol 39* 4 — — — — — — 40* 8* 9.3 16.3*
HDL 45* 2 — — — — — — — — 15.7* 9.4
LDL 40* 7 — — — — — — — — 24.3* 10.2
Fibrinogen — — 33.6* 13.7* 44 0 29.7* 0 23 16* 22.5* 11.7*
FII — — 49.2* 0 57 0 70* 4.1 — — 0 20.8*
FV — — 44* 13* — — 71.4* 2.8 — — 0 9.3*
FVIIIC — — 40* 0 — — — — — — 5.9 12.1
vWF — — 31.8* 0 75 0 25.3* 30.7* — — 23.4 15.8*
Antithrombin — — 48.6* 0 — — 6 33.5* — — 0 30.0*
Protein C — — 50* 0 — — 40.6* 4.4 — — 17.7* 20.1*
Protein S — — 22* 21* — — 10.5 37* — — 14.9 33.2*
Protein Z — — — — — — 67* 6.6 — — 42.3* 30.2*
Plasminogen — — 23.6* 0 — — — — — — 18.2 20.3*
TFPI — — 51.6* 0 — — — — — — 0 24.8*
D-dimer — — 10.9 0 65 — 7 5.2 — — 0 7.5
Prothrombin fragment F1.2 — — — — 45 — 22* 44* — — 0 R
Abbreviations: —, no data; max, maximum; min, minimum; R, removed from the model; SAFHS, San Antonio Family Heart Study. 
*p < 0.05.might be explained mainly by age and AIS as
CVD origin. 
A limitation of such a study is that a
measurement error can be associated with
decreased heritability estimates, as discussed by
Souto et al. (2000). The lower heritability esti-
mates presented here, however, are unlikely to
be caused by measurement error, as the
intraassay coefﬁcients of variation (ICV) and
run-to-run coefficients of variation (RCV)
reported for the methodologies used were
small, for example, ranging from 1.3% (vWF)
to 6.2% (F1.2) for ICV and 3.3% (FVIIIC) to
9.5% (F1.2) for RCV, respectively (Kreuz
et al. 2006). In addition, data reported here
are limited to the cohort investigated—that is,
white German stroke children. As outlined,
our family-based study sample consists of
nuclear families with one or more ﬁrst-degree
siblings (no half-siblings) and their parents
who were ascertained via index patients. To
partly accommodate the nonrandom sam-
pling, we conditioned our analyses on the phe-
notype of the initial proband (Comuzzie and
Williams 1999). However, we cannot rule out
that the reported estimates for h2r and c2 may
be overfit and are not representative of the
general population. 
In conclusion, in addition to the strong
heritability estimates found for Lp(a) kringle 4
repeats and Lp(a) concentrations and, to a
lesser extent, for protein Z, LDL, ﬁbrinogen,
and protein C, our findings strengthen the
importance of shared environmental influ-
ences of lipids and levels of coagulation factors
during childhood and early adulthood, hereby
pointing to the potential for family-based
lifestyle interventions. Along with the diagnos-
tic workup of known prothrombotic polymor-
phisms associated with stroke onset in white
German children (Düring et al. 2004; Nowak-
Göttl et al. 1999a, 1999b; Sträter et al. 2002),
the main focus on AIS studies in this cohort
will include future research to identify novel
genes involved in the control of quantitative
trait loci, as well as environmental risk factors
with a strong c2 effect (such as smoking) as the
main factors essential in prevention of AIS in
children. Families with affected subjects are
advised to change their lifestyle to reduce their
CVD risk for future offspring. 
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